Alpine Woods Capital Investors LLC Acquires 39,199 Shares of Kenvue Inc. (NYSE:KVUE)

Alpine Woods Capital Investors LLC increased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 14.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 308,165 shares of the company's stock after acquiring an additional 39,199 shares during the period. Kenvue makes up about 1.2% of Alpine Woods Capital Investors LLC's holdings, making the stock its 21st biggest position. Alpine Woods Capital Investors LLC's holdings in Kenvue were worth $6,579,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its stake in Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company's stock worth $3,189,985,000 after buying an additional 3,075,019 shares in the last quarter. State Street Corp grew its stake in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after buying an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock worth $2,011,832,000 after buying an additional 7,115,374 shares in the last quarter. Geode Capital Management LLC grew its stake in Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock worth $1,029,810,000 after buying an additional 399,846 shares in the last quarter. Finally, Harris Associates L P grew its stake in Kenvue by 7.5% in the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock worth $727,658,000 after buying an additional 2,186,114 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Remove Ads

Kenvue Trading Down 0.3 %

NYSE KVUE traded down $0.07 during trading on Tuesday, hitting $23.35. The company had a trading volume of 16,840,611 shares, compared to its average volume of 16,125,580. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a market cap of $44.62 billion, a price-to-earnings ratio of 44.05, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company's fifty day moving average is $21.89 and its 200-day moving average is $22.40.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.51%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

A number of research firms have commented on KVUE. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research note on Friday, January 17th. Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Piper Sandler upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and cut their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, UBS Group cut their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Kenvue has a consensus rating of "Hold" and a consensus target price of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.